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Abstract 
Autophagy has attracted a lot of attention in recent years. More and more proteins and signaling 
pathways have been discovered that somehow feed into the autophagy regulatory pathways. 
Regulation of autophagy is complex and condition-specific, and in several diseases, autophagic 
fluxes are changed. Here, we review the most well-established concepts in this field as well as the 
reported signaling pathways or components which steer the autophagy machinery. Furthermore, 
we will highlight how autophagic fluxes are changed in various diseases either as cause for or as 
response to deal with an altered cellular homeostasis and how modulation of autophagy might be 
used as potential therapy for such diseases. 
Key words: Autophagy, ATGs, mTOR, UPR, FOXO1, HSF1, Heat Shock Proteins (HSP), Human 
diseases. 
INTRODUCTION 
Autophagy, as a dynamic and fundamental 
process, has been reported to play roles in develop-
ment, differentiation, cell repair, immunologic de-
fense as well as protein quality control. Ensuring the 
diverse and proper functioning of autophagy in cells 
has been highlighted as an important aspect for the 
maintenance of cellular homeostasis. Inversely, fail-
ures in autophagic regulation have been associated 
with many pathological processes, such as muscle 
atrophy, neurodegeneration, tumor development and 
aging.  
It has been generally accepted that the dynamic 
autophagic process is mainly executed by a series of 
proteins, encoded by the so-called AuTophagy related 
Genes (ATGs). Although the number of ATG(s) is still 
increasing, the function of most ATG(s) has been well 
characterized to orchestrate the dynamic process of 
the formation of pre-autophagosome, the maturation 
of autophagosome and the fusion with lysosome. As 
the autophagic process can be affected either by pro-
ducing autophagosomes or by degrading autopha-
gosomes, the concept of the autophagic flux has been 
introduced which is generally used as an indicator of 
the activity of entire autophagic process.  
The core machinery of autophagy, consisting of 
the ATG(s), is regulated by many signaling pathways 
such as the mTOR pathway, the insulin pathway and 
the ER stress response. How the signals are trans-
ferred to lead to activation of autophagy is still far 
from being understood and they may occur via both 
direct interactions with pre-existing ATGs and tran-
scriptionally up-regulation of the ATGs (1-4).  
Based on what has been explored about the au-
tophagic network, we review here: 1) the core ma-
chinery of ATG(s), 2) the signaling pathways affecting 
the autophagic flux and 3) the implications of au-
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tophagy in human diseases. 
TYPES OF AUTOPHAGY 
Since the 1960s, autophagy has been gradually 
recognized as an important catabolic process. The 
main aim of autophagy is to recycle and reallocate 
cellular components to satisfy the change of energy 
requirement or to decrease the accumulation of toxic 
products. As such, autophagy is responsible for re-
moving long-lived proteins, damaged organelles and 
protein aggregates. So far, three types of autophagy 
have been reported, respectively named macroau-
tophagy, microautophagy, and chaperone-mediated 
autophagy (CMA) (see figure 1). The common feature 
they all share is that the cargo is eventually delivered 
into lysosomes for degradation. However, the way of 
cargo delivery is different.  
Macroautophagy is a multi-step and 
time-consuming journey for cargo wrapping and de-
livery. A complete process includes membrane initia-
tion, nucleation, elongation (expansion), autophago-
some maturation and the fusion with lysosome (see 
figure 1A). Notably, the double-membrane structure 
in autophagy is similar to those of other cellular 
plasma membranes, such as the endoplasmic reticu-
lum, the trans-Golgi network, and mitochondria. The 
origin of autophagosomal membranes however is still 
obscure. Because of its complexity, autophagy has to 
be controlled precisely. On one hand, the main regu-
lation of autophagy requires a specific group of mol-
ecules named Autophagy-related genes (ATGs). Until 
now, more than 30 ATGs have been discovered in 
yeast (5) and they are highly conserved among eu-
karyotes (6). On the other hand, there are many sig-
naling pathways involved in macroautophagic induc-
tion such as the mTOR pathway, endoplasmic retic-
ulum (ER) stress signals, the insulin pathway, and 
calcium signaling.  
In microautophagy, the cargo is directly en-
gulfed by the lysosome itself. Here, the targeted re-
gion of lysosomal membrane undergoes invagination, 
protrusion and/or septation to enclose the cargo for 
degradation (7) (see figure 1B). Under both basal and 
stress conditions, microautophagy has been reported 
to be involved in energy balance maintenance (8, 9). 
Chaperone-mediated autophagy (CMA) uses 
KFERQ-like sequences in proteins to deliver them into 
the lysosome (10). The recognition of cargo and its 
delivery to the lysosome-associated membrane pro-
tein type-2A (LAMP-2A) is mediated by the HSPA8 
(Hsc70)-containing chaperone complex (11-13) (see 
figure 1C).  
Macroautophagy, the bulky and low-selective 
form of autophagy is the most investigated type, es-
pecially in relation to cellular health and pathology. 
Therefore, in this review we will mainly focus on the 
regulation of macroautophagy (hereafter generally 
referred to as autophagy) as well as its involvement in 
human diseases. 
 
 
Figure 1. Overview of the different forms of autophagy in mammals. Macroautophagy, microautophagy and chaperone-mediated autophagy are 
three types of autophagy in mammals. Here, the main steps in these processes as well as the most important characteristic structures and the related 
mediators are presented. 
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REGULATION OF 
MACROAUTOPHAGY  
Considering the multiple roles of autophagy in 
both physiological and pathological processes, better 
understanding how autophagy is regulated in cells 
may enlarge our knowledge of the maintenance of 
homeostasis, as well as facilitate the development of 
efficient therapies for patients. 
Autophagosomal initiation, nucleation and 
maturation 
The precise collaboration of ATGs is essential for 
performing autophagy successfully. Based on their 
functions, especially derived from detailed studies in 
yeast, ATGs have been divided into 6 groups: 1) the 
ATG1/ULK1 kinase complex, 2) ATG9, 3) the class III 
phosphatidylinositol (PI)3–kinase complex 
(ATG6–ATG14-Vps15–Vps34), 4) the PI(3)P-binding 
ATG2–ATG18 complex, 5) the ATG12 conjugation 
system (ATG12–ATG5–ATG16), and 6) the ATG8 
conjugation system (ATG8–phosphatidylethano-
lamine (PE)). (See figure 2 and table 1). 
 
Figure 2. Overview of the main steps in autophagy and the main genes involved. 
 
Table 1. The nomenclature and functions of ATGs in yeast and mammals. 
Yeast Mammals Functions 
Atg1 ULK1, ULK2 Serine/threonine protein kinase required for vesicle formation 
Atg2 ATG2A, ATG2B Forms a complex with Atg18 
Atg3 ATG3 An E2-like enzyme, which catalyzes the lipidation of Atg8-like proteins (GABARAP, GABARAPL1, 
GABARAPL2 or MAP1LC3A); which also autocatalyzes itself to form Atg12-Atg3 complex for maintaining 
mitochondrial homeostasis. 
Atg4 ATG4A, B, C, D Cysteine protease: Atg8 processing and activation. 
Atg5 ATG5 Forms the Atg12-Atg5 complex, which plays E3-like activity for Atg8 lipidation 
Atg6 Beclin-1 Forms the Vps34 PI3K complex 
Atg7 ATG7 An E1 enzyme that mediates Atg8 lipidation and Atg12-Atg5/Atg3 interaction 
Atg8 LC3/MAP1LC3A, 
GATE-16/GABARAP 
Modifier, involves in formation of autophagosomal vacuoles through conjugating to PE. 
Atg9 ATG9A, ATG9B Cycles between a juxta-nuclear trans-Golgi network compartment and late endosomes, and interacts with the 
Atg2-Atg18 complex. 
Atg10 ATG10 An E2-like enzyme that catalyzes the conjugation of Atg12 to Atg5. 
Atg12 ATG12 Conjugated to Atg3 and Atg5 
Atg13 ATG13 Downstream target of mTOR signaling pathway: the Atg1-Atg13-Atg17-Atg101 complex 
Atg14 ATG14 Component of Vps34 PI3K complex 
Atg16 ATG16L Forms the Atg16L-Atg12-Atg5 complex 
Atg17 RB1CC1/FIP200 Component of Atg1/ULK1 complex: Atg1-Atg13-Atg17-Atg29-Atg31 in yeast, and 
ULK1/2-Atg13-FIP200-Atg101 in mammals 
Atg18 WIPI-1,2,3,4 Forms the complex with Atg2. 
Atg29 ? Component of Atg1 complex 
Atg101 ATG101 Component if the ULK1/2 complex 
The ATGs uncovered so far as well as ATG functions are listed. Abbreviations: GABARAP is GABA(A) receptor‐associated protein; MAP1LC3A/MAP1LC3B is microtu-
bule‐associated proteins 1A/1B light chain 3. ATG16L: autophagy related Atg 16‐like; RB1CC1 is RB1‐inducible coiled‐coil 1. FIP200 is 200 kDa FAK family kinase‐interacting 
protein. WIPI‐1,2,3,4 is WD repeat domain, phosphoinositide interacting 1. 
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1) Autophagy is initiated by forming a lipid bi-
layer, which is either newly synthesized or budded 
from existing membranes in the cytoplasm (14). In 
Saccharomyces cerevisiae, the initiation site is defined as 
the pre-autophagosomal structure (PAS) (15). The 
serine/threonine-protein kinase ATG1 containing 
complex, supported by ATG13-FIP200-ATG101 
(16-18), works as the most upstream component of the 
core autophagy machinery, especially after starvation 
(19). Unc-51 like kinase 1 and 2 (ULK1 and ULK2) are 
the mammalian homologues of ATG1. In yeast, ATG1 
forms a complex with ATG13, ATG17, ATG29 and 
ATG31. However, the mammalian ULK complex has 
different components, including ULK1/2, ATG13, 
FIP200 and ATG101. 
2) To facilitate membrane transport for the ex-
pansion step, ATG9, the autophagy-specific phospha-
tidylinositol 3-kinase (AS-PI3K) complex, 
ATG2-ATG18 and ATG12–ATG5–ATG16 are re-
quired. ATG9, the sole integral membrane protein, 
facilitates autophagic membrane transport (20).  
3) The components of the AS-PI3K complex are 
different in yeast and mammals. In yeast, there are 
two PI3K complexes, ATG30–ATG14-Vps15–Vps34 
and ATG30-Vps38-Vps15-Vps34, which respectively 
function in autophagy and vacuole protein sorting 
(21, 22). Among these components, Vps34 is the one 
known to have PI3K activity. Similarly, the mamma-
lian homologue of Vps34, also known as PI3K class III 
(PI3KC3), is involved in both autophagy and endo-
somal trafficking. The mammalian AS-PI3K com-
plexes are more elaborate than in yeast. They consist 
of Vps15, Vps34, ATG14, Beclin-1, UVRAG, Rubicon 
and probably more components (23, 24). Among 
them, Beclin-1 (the mammalian homologue of ATG6) 
is the crucial one differentiating the autophagic 
PI3KC3 complex from the endosomal one, and it is 
essential for autophagosome formation (25). Beclin-1 
can either up-regulate or down-regulate autophagic 
activity through binding with different partners. 
Ambra1, Bif-1, and VMP-1 are Beclin-1 partners that 
activate autophagy, whereas, its partners Bcl-2, 
ICP34.5 and M11 inhibit autophagy (26-28).  
4) The ATG2–ATG18 complex is required for 
nucleation. Especially its PtdIns(3)P-binding ability is 
critical for the complex to localize to autophagic 
membranes, endosomes or vacuolar membrane (29).  
5) The ATG12–ATG5–ATG16 complex mediates 
ATG8 lipidation (see next paragraph). The activating 
process of ATG12 shares similarities with the ubiqui-
tin-ligation process (consisting of an E1-ubiquitin ac-
tivating enzyme and E2-ubiquitin-conjugating en-
zymes): ATG7, as E1-like protein, firstly catalyses 
ATG12 to become an active form, and next ATG10 (an 
E2-like protein) facilitates the active ATG12 to bind 
with ATG5. ATG12–ATG5 further assembles into a 
350kD complex by interacting with the small 
coiled-coil protein ATG16 which is essential for au-
tophagy (30). 
6) The ATG8 conjugation to phosphatidylethan-
olamine (PE) is crucial for autophagosomal expansion 
and maturation. Therefore, ATG8 or its mammalian 
homologue, LC3, is generally used as a marker to 
trace the autophagic process (see next section) (31, 32). 
To fulfill ATG8-PE conjugation (ATG8 lipidation), 
two possible routes can be used. One is via assisted 
assembly by the ATG12–ATG5–ATG16 complex 
mentioned above (33); another is via processing LC3 
itself. Newly synthesized LC3 is firstly cleaved by 
ATG4 to become a cytosolic form (LC3 I), then a frac-
tion of LC3I is further activated by ATG7 (an E1-like 
protein) (34) and ATG3 (an E2-like protein) (35) to 
become LC3II (the membrane-binding form). Even 
though the core machinery of autophagy has been 
rolled out as being complex already, the number of 
components discovered to be involved in this network 
still increases (36). 
MEASURING THE AUTOPHAGIC 
FLUX 
The activity of autophagy is controlled by au-
tophagosomal formation (input) and autophagosomal 
degradation (output). Therefore, the speed of the au-
tophagosomal turnover is defined as autophagic flux, 
which is the real indicator of autophagic activity. How 
to measure the autophagic flux has been excellently 
described elsewhere (37). 
Here, we only shortly summarize the markers 
and inhibitors that are most commonly used.  
1) As mentioned above, LC3 lipidation is essen-
tial for autophagy to proceed. This lipidation of LC3 
can be demonstrated by western blot analysis (WB) 
(38). Upon an increase in autophagosomes, the band 
of LC3 will shift from LC3I (18kDa) to LC3II (16kDa) 
on SDS-PAGE. Upon time after autophagic activation, 
levels of LC3II will decline again because it is 
co-degraded with the autophagic cargo in lysosomes. 
Whilst LC3 data are indicative of a changed au-
tophagic flux, they cannot distinguish whether more 
autophagy is induced or whether autophagoso-
mal-lysosomal fusion is impaired, unless accurate 
kinetics are studied. To distinguish between these 
possibilities, one can block either the synthesis or 
degradation of LC3II using autophagic inhibitors (see 
figure 3). Wortmannin and LY294002 can inhibit the 
autophagosome formation: if LC3 is still lipidated by 
the experimental condition in the presence of these 
inhibitors, this implies that autophagoso-
mal-lysosomal fusion was impaired. Bafilomycin A1 
and the inhibitors of lysosomal proteases (such as E64, 
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pepstatin A, chloroquine) stop LC3II degradation, 
This in itself will further increase LC3II levels; if un-
der the experimental condition LC3II levels even fur-
ther increase, this then implies that the condition has 
led to an increased autophagosome formation. 
2) p62/SQSTM1 is thought to be responsible for 
cargo selecting and transport of proteins or protein 
aggregates (not organelles), and is also co-degraded 
with its cargo in lysosomes (39). Thus, p62 degrada-
tion can also be used to measure the autophagic flux, 
which should then be delayed by bafilomycin A1 and 
the inhibitors of lysosome proteases. 
Besides measuring LC3II and p62 biochemically, 
one can also use microscopic analyses as they form 
characteristic puncta. The number of these puncta can 
be counted as (semi) quantitative analyses of au-
tophagy. 
3) Still the best way to analyze the induction of 
autophagy and to demonstrate that the observed 
puncta/vesicles are indeed autophagosomes is by 
using Electron Microscopy(EM) in which it can be 
recognized as a vesicle surrounded by a double 
membrane that contains cytosol, protein aggregates, 
and/or organelles that look morphologically intact. 
AUTOPHAGY REGULATING 
SIGNALING PATHWAYS 
Autophagy is regulated by many signaling 
pathways. The most established ones of these are 
discussed below. 
The mTOR pathway 
The mTOR (mammalian target of rapamycin) 
serine/threonine kinase is a well-characterized and 
critical node of cell metabolism (40) and (besides con-
trolling autophagy) mainly regulates ribosomal bio-
genesis and protein translation (41). The mTOR 
pathway is the most extensively studied network for 
autophagy regulation because of its ability to timely 
sense the nutrient state, growth factors availability 
and stress (42). It is still unclear how mTOR itself is 
regulated, although the phosphatidylinositol 3-kinase 
(PI3K)–AKT/protein kinase B (PKB) (43), TSC1/TSC2 
(44, 45), Rheb (Ras homolog enriched in brain) (43), 
PRAS40 (46) and DEPTOR (47) have been found as its 
regulators under different conditions.  
So far, two distinct mTOR complexes have been 
found in mammals (see figure 4).  
(i) The first complex, mTORC1, includes mTOR, 
the mammalian LST8/G-protein β-subunit like pro-
tein (mLST8/GβL), and the regulatory-associated 
protein of mTOR (Raptor). Based on the observation 
that the FKBP12–rapamycin complex can destabilize 
the mTOR-GβL-Raptor complex (41), rapamycin has 
been generally used as a mTORC1 inhibitor leading to 
autophagy induction (48, 49). As substrates of 
mTORC1, S6K1 (50) and 4E-BP1 (51) can be modu-
lated to change the recruitment of ribosomal subunits 
as well as the efficiency of cellular translation, thereby 
balance the protein synthesis to fit with cellular re-
quirement for energy. For this reason, the phosphor-
ylated state of S6K1 and 4E-BP has been considered as 
a convenient indicator of mTORC1 activation (52). 
(ii) The second complex, mTORC2 consists of 
mLST8/GβL and Rictor (rapamycin-insensitive com-
panion of mTOR). This branch regulates the 
Akt-FOXO axis and the PKCα pathway, but not S6K1 
or 4EBP1 (53). mTORC2 has been considered as ra-
pamycin-insensitive complex (54). Nevertheless upon 
prolonged treatment, rapamycin also impedes on 
mTORC2 (55).  
 
 
 
Figure 3. The autophagic flux and 
generally used inhibitors. Inside 
the square, the autophagic flux is 
depicted. This is a dynamic process 
that can be modulated by the indicated 
drugs (grey text boxes) by affecting 
autophagosome induction and expan-
sion (ON-rate) or by affecting au-
tophagosome fusion or degradation 
(OFF-rate). 
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Figure 4. Regulation of the two mTOR complexes. mTORC1 is able to sense the amino acid concentration and energy state directly, but needs the 
PI3K-AKT axis to sense growth factor status. The downstream effects of mTORC1 are mainly mediated by 4E-BP1 and S6K1, which can be inhibited by the 
rapamycin-FKBP12 complex. mTORC2, as a brake-like inhibitor, decreases the extent of AKT-induced mTORC1 activation. 
 
Calcium signaling pathway 
Calcium signaling is another generally studied, 
but still obscure pathway by which autophagy can be 
regulated. In cells, a stable calcium concentration is 
maintained by Ca2+ channels through two independ-
ent but closely linked processes (56): 1) a slow, sus-
tained entry of extracellular calcium, and 2) a rapid, 
transient release of calcium from stores in the ER. To 
replenish or maintain Ca2+ stores, Voltage-Operated 
Channels (VOCs), Receptor-Operated channels 
(ROCs) and Store-Operated Channels (SOCs) are re-
quired (56, 57). Importantly, Ca2+ release is only me-
diated by inositol 1,4,5-trisphosphate (InsP3/IP3) re-
ceptors (IP3Rs) in the ER that thus play a critical role 
in transient Ca2+ signaling (56). Not surprisingly, IP3R 
and TRPML3 (a member of the TRPML subfamily of 
the transient receptor potential (TRP) channel super-
family) have been shown to respectively inhibit and 
promote autophagy (58, 59). In line with this, it has 
been also shown that the expanding ER is a potent 
stimulator of autophagy (60).  
Importantly, the concentration of calcium di-
rectly links with the activity of calcium-sensitive ki-
nases and proteases. On one hand, Calmodu-
lin-Dependent Kinase Kinase-β (CaMKKβ) (61), 
elongation factor-2 kinase (eEF-2 kinase; 
Ca2+/calmodulin-dependent kinase III) (62) and 
AMP-activated protein kinase (AMPK) (63) will be 
activated by abnormal cytoplasmic concentrations of 
calcium under stressed conditions. Each of these up-
stream sensors will immediately transmit the signals 
to downstream substrates for adjusting cellular me-
tabolism in new microenvironment and autophagy 
will be activated to release more amino acids under 
these conditions. On the other hand, higher Ca2+ con-
centration increases activity of calpain which can 
cleave ATG5, thereby inhibits autophagosome for-
mation (64). 
The Unfolded Protein Response 
Except being an important regulator of cytosolic 
calcium concentration, the ER is the main cellular 
protein factory that synthesizes membrane bound and 
secretory proteins (65). Protein homeostasis in the ER 
is controlled by the Unfolded Protein Response (UPR) 
that consists of three parallel branches: activating 
transcription factor 6 (ATF6), double-stranded 
RNA-activated protein kinase (PKR)–like ER kinase 
(PERK), and inositol requiring enzyme 1 (IRE1). These 
branches serve to not only increase the folding capa-
bility of the ER (through induction of chaperones), but 
also enhance the degradation capability. This involves 
both ER-associated proteasomal degradation (ERAD) 
as well as autophagy (see figure 5) (66).  
(i) IRE1 (an endoribonuclease, presents in the ER 
membrane) is the most conserved branch of the UPR 
(67). Once activated, IRE1 cleaves the mRNA of XBP1 
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(X-box binding protein 1). This step produces XBP1s 
(the spliced mRNA) which transcriptionally 
up-regulates UPR related genes. Generally, IRE1 is 
responsible as the driving force of the entire UPR gene 
program(68). XBP1 also up-regulates the 
BAG3/HSPB8 complex (69), which recently has been 
found to be involved in the induction of autophagy 
(70).  
(ii) ER located ATF6 can be cleaved by site-1 and 
site-2 protease (S1P and S2P) to yield a cytosolic 
fragment (ATF6c) that can translocates into the nu-
cleus for up-regulating UPR genes, such as BiP (the 
ER-resident chaperone of the heat shock protein 
HSP70 family), protein disulfide isomerase (PDI) and 
GRP94 (glucose-regulated protein 94, the ER-resident 
chaperone of the Hsp90 family) (71). Whilst the ATF6 
pathway primarily serves to induce the expression of 
ER chaperones, ATF6 can also up-regulate the au-
tophagy-inducing BAG3/HSPB8 complex under cer-
tain conditions (Minoia et al., unpublished), indicat-
ing that also this UPR-branch can increase the au-
tophagic flux.  
(iii) The 3rd UPR branch, PERK, has as main 
function to decrease the burden of newly synthesized 
ER proteins. PERK phosphorylates and inactivates 
translation initiation factor 2α (eIF2α), which causes a 
general block in mRNA translation. Meanwhile, ATF4 
is specially induced by eIF2α through recognizing its 
5׳-untranslated region, allowing the selective 
up-regulation of transcription factor C/EBP homolo-
gous protein (CHOP) and the activation of growth 
arrest and DNA damage–inducible 34 (GADD34). 
GADD34 then plays as a negative feedback loop for 
the response essential for cell survival (72, 73). Inter-
estingly, however, ATF4 is also involved in autopha-
gy activation as it leads to the induction of ATG12 
(74).  
Insulin (IS) pathway  
As one of the most important signaling path-
ways in cell metabolism, the Insulin/IGF (insulin-like 
growth factors) axis is responsible for promotion of 
cell proliferation and inhibition of cell death, which 
are mediated mainly by the PI3K–AKT/PKB pathway 
and the Ras–mitogen-activated protein kinase 
(MAPK) pathway (75-77). The Insulin/IGF axis has 
many substrates, two of which being the forkhead box 
O class transcription factors (FOXOs) and the heat 
shock transcription factor 1 (HSF1) (78). Whilst the 
FOXO pathway has in various ways been linked up 
with protein degradation systems, especially au-
tophagy (1, 79), the HSF1 branch of this network has 
been mainly thought to be involved in enhancing the 
protein folding capability of cells (80). Yet, also HSF1 
activity can lead to enhancement in autophagic activ-
ity (see below). 
Most of the pioneering studies on FOXO and 
HSF1 were done in C. elegans. Both DAF16 (FOXO 
homologue in C. elegans) and HSF1 were found to be 
crucial for the downstream effects of the insulin 
pathway on life span and the ability to handle dis-
eases associated (misfolded) proteins (81-84). Below, 
we will shortly summarize those data. 
(a) FOXO  
While there is only one DAF-16 in C. elegans and 
one dFOXO in flies, the mammalian FOXO family in-
cludes 4 members, FOXO1/FKHR, FOXO3/FKHRL1, 
FOXO4/AFX, and FOXO6 (85). FOXO6, expressed in 
a specific temporal and spatial pattern, is believed to 
be mainly involving in brain development (86). Cur-
rently, FOXO1, FOXO3 and FOXO4 are known to 
share the most elementary and conserved sequence 
motifs as well as modification features (87): 1) the 
DNA-binding domain (or forkhead (FKH) domain), 
which recognizes (G/C)(T/C)AAA(C/T)AA or 
TT(G/A)TTT(G/A)(G/C) in the promoter of target 
genes in mice; 2) the three AKT1-phosphorylation 
sites (Thr24, Ser256, and Ser319 in human FOXO1) 
that mediate nuclear-cytoplasm shuttling (88, 89). 
Generally, the members of the family can compensate 
for each other (90). However, in knock-out mice dif-
ferent FOXOs do show some specific functions and 
expression patterns: FOXO1 in vascular development, 
FOXO3 in ovarian follicular development, and 
FOXO4 without any distinguishable phenotype(91).  
Nuclear (active)-Cytoplasm (inactive) shuttling 
is a critical and generally accepted model for regulat-
ing the transcriptional activity of FOXOs. Except for 
the PI3K–AKT/PKB pathway that mediates the nu-
clear export of FOXO, many other upstream modula-
tors do in parallel affect the location of FOXOs, in-
cluding various kinases and phosphatases (SGK, CK1, 
AMPK, JNK, MST1, IKKβ, DYRK1, CDK2, and PP2A), 
acetylases and deacetylases (CBP/P300, PCAF, 
SIRT1/2) and ubiquitinases and deubiquitinases 
(USP7/HAUSP, and Skp2)(87, 92). Irrespective of how 
FOXOs are activated, the consequence will be a 
change in the expression profile of its large set of tar-
get genes that regulate many cellular processes in-
cluding autophagy (93) (see table 2). In line, altera-
tions in FOXOs activity have also been related to 
many pathological processes, such as diabetes, cancer, 
infertility, cardiovascular disorder, immune system 
dysfunction, neurodegeneration and ageing (94-97).  
Regarding the role of FOXOs in autophagy two 
models of action have been described. In line with its 
function as transcription factor, FOXO3 can induce 
autophagy through transcriptionally up-regulating 
LC3, Gabarapl1, Vps34, ULK2 and ATG12(99). 
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FOXO3 induced autophagy entirely seems to depend 
on FOXO1 since lack FOXO1 prevents FOXO3’s func-
tion in autophagy (106). Surprisingly, however, 
FOXO1 (also) can boost the autophagic flux in a tran-
scription independent manner by direct binding to 
ATG7 in the cytosol (1). This novel and unprece-
dented action of FOXO1 might explain to some extent 
why DAF-16 mediates such a large life span expan-
sion and leads to pronounced protection against 
neurodegenerative protein aggregation diseases in C. 
elegans (107, 108) (also see below). 
 
Table 2. The downstream targets of FOXOs. 
Target genes (ref) Cellular processes Consequences  
p21Cip1, p27Kip1 (98) 
 
Cell cycle Oncogenesis 
FasL, Bim, Bnip3 
(98) 
 
Apoptosis 
LC3, Gabarapl1, 
Vps34, ULK2, and 
ATG12 (99) 
Autophagy Longevity 
Suppression of 
neurodegeneration 
Catalase, Sod2, 
Gadd45, DDB1 
(98), caveolin-1 
(100) 
Stress resistance 
Sprouty2, PBX1 
(90), Cited2 (101) 
Angiogenesis Differentiation 
BTG1, KLF4 (102), Differentiation 
NPY (neuropeptide 
Y ), Agrp (Agou-
ti-related protein) 
(103), Pomc (104) 
Food intake Metabolism 
Atrogin-1, MuRF1 
(105) 
Ubiquitin-proteasome Muscular Degen-
eration 
 
(b) HSF1  
As another downstream target of the Insu-
lin/IGF axis, HSF1 is essential for development and 
stress resistance (109). HSF1 is known as the major 
factor involved in the up-regulation of heat shock 
proteins serving to restore proteostasis in the cytosol 
(81, 110). Under stress conditions, HSF1 is thought to 
release from the Hsp90 docking complex that nor-
mally keeps it inactive under non-stress conditions, 
and may undergo some structural changes by not yet 
elucidated mechanisms. Then, HSF1 translocates into 
the nucleus where it gets hyperphosphorylated and 
binds to HSE in promoter of target genes (mainly 
HSPs). Next, the acetylation of HSF1 seems required 
for its release from DNA and the turn-off of gene ex-
pression (111).  
In mammalian cells, HSPs are divided into HSPC 
(HSP90), HSPA (HSP70), DNAJ (HSP40), HSPB (small 
HSP) and chaperonins (CCT, GroES/EL) (112). Whilst 
HSF1 regulated HSPs generally seem to serve in either 
protein folding or proteasomal degradation, recent 
evidence has suggested that some of its target HSP 
genes are also linked to autophagy. E.g. Carra et al 
demonstrated that HSPB8 in complex with BAG3 and 
Hsp70 can increase the autophagic flux and thereby 
enhance the clearance of protein aggregates which 
arise during neurodegenerative diseases (70, 113) (see 
figure 6). Except as UPR target genes (see figure 5), 
HSPB8 and BAG3 can also be induced by activation of 
HSF1 (114). Another small HSP, HSPB7, also serves in 
autophagic clearance of model aggregation putatively 
through improving loading of cargo (the aggregates) 
into autophagosome (115). How HSPB7 is regulated, 
however, is still unknown.  
THE ROLE OF AUTOPHAGY IN 
NORMAL PHYSIOLOGY AND 
DISEASE  
Physiological roles of autophagy 
Autophagy has mostly been studied as a mean of 
cells to cope with acute or chronic stresses, where 
metabolism needs to be adjusted rapidly to fit with 
the changed microenvironments (116-118). However, 
autophagy is also indispensable under nor-
mal-growth conditions (64, 119) and the physiological 
roles of autophagy include: 
(a) Nutrients recycling  
Through degradation of cellular materials, au-
tophagy facilitates an efficient and dynamic energy 
conversion of amino acids, glucose, lipids and nuclear 
acid, especially under conditions of starvation (118, 
120, 121). 
(b) Cell self-Repair  
Autophagy is required for removal of damaged 
mitochondria (mitophagy), peroxisomes (pexophagy) 
and protein aggregates (aggrephagy) as arise during 
normal cell growth (39, 122).  
(c) Protein quality control  
Protein quality control is mastered accurately by 
balancing protein synthesis, protein folding and pro-
tein degradation. Unlike steric considerations for 
proteasomal degradation, autophagy shows more 
general or non-selective property. Autophagic and 
proteasomal degradation are closely linked with each 
other, which is exemplified by a boost of autophagy 
after proteasome inhibition (123, 124).  
(d) Cell maturation and differentiation  
As evidenced from the phenotype in ATG 
knock-out mice, autophagy also affects differentiation 
(125). Similarly, in Drosophila, autophagy is essential 
for remodeling of the larval mid-gut as well as the 
development of the larval salivary gland (126).  
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(e) Infection and immunity  
Autophagy is involved in both bacteria-related 
and virus-related infectious processes (127-129). In 
addition, Beclin1/Atg6 mediated autophagy impedes 
on lymphocyte development (130).  
 
Figure 5. The different branches of the Unfolded Protein Response (UPR) and autophagy. The UPR is mediated by the ATF6, PERK, and IRE1 
pathways. 1) After cleavage, ATF6 is able to up-regulate the expression of chaperones. 2) PERK is responsible for eIF2α activation. Activated, phos-
phorylated eIF2α-p then inhibits translation initiation, meanwhile stimulates ATF4 to transcriptionally activate CHOP and Atg12. In addition, ATF4 also 
activates GADD34 to decrease the activity of eIF2α-p, which forms a feedback loop. 3) IRE1 cleaves XBP1 to increase the expression of chaperones as well 
as speed up ERAD. 
 
Figure 6. Protein homeostasis is mainly maintained by HSF1 and FOXO, two downstream targets of the insulin pathway. The formation 
of biochemistry-detectable aggregates is a dynamic process, which is initiated by accumulation of unfolded/misfolded proteins (Phase I), facilitated by the 
formation of intermediates (Phase II) leading to the appearance of detectable aggregates (Phase III). This process can be intervened by different cellular 
strategies, including HSPs mediated folding/refolding, as well as proteasome- and autophagy-mediated degradation. HSPs, up-regulated by HSF1 and FOXO, 
are mainly responsible for Phase I, in which the misfolded proteins can be either refolded to become functional normal proteins or degraded if refolding is 
unsuccessful. Once the intermediates are formed, autophagy starts playing a more important role. At the beginning of Phase II, the intermediates can still 
be handled by either HSPs or proteasome, and this response supposedly requires FOXO. At both Phase II and III, FOXO is also involved the induction of 
autophagy to clear large(r) protein aggregates. 
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(f) Cell death  
Controlling cell fate properly is important for 
development, differentiation and tumor suppression. 
Autophagy initially provides the adaptive response to 
micro-environmental change or stress. However, if 
the stress persist or the amount of inflicted damage 
goes beyond of cellular tolerance, exaggerated au-
tophagy will lead to cell death and thus remove the 
damaged cells to maintain tissue and organismal in-
tegrity. As such, autophagy parallels apoptosis which 
also primarily serves as a cell remodeling process 
under stresses, but if over-activated helps cell elimi-
nation (131). 
Autophagy and diseases  
Deregulation of autophagy has been linked with 
loss of cell function leading to organismal pathologies 
(132, 133). In many cases, it is not clear whether de-
regulation of autophagy itself is the trigger for such 
pathologies or just a mere consequence and reflection 
of alterations in the amount of cargo for the au-
tophagic degradation. Below, a few links between 
altered autophagy and diseases will be summarized. 
(a) Tumor development  
Tumorigenesis is a multi-step process, involving 
oncogenes and tumor suppressor genes. Several of 
these genes, e.g. p53, FOXOs, TOR, SirT1/2, Bcl-2, 
PTEN, Ras, NF-κB and series of micro RNAs, also 
have effects on autophagy (134). On one hand, au-
tophagy could directly play a role in tumor suppres-
sion. Firstly, mutations in or deletion of Beclin-1, 
which is the essential ATG for autophagy initiation 
are found in 40–75% of cases with human breast, 
ovarian or prostate cancer (25). Even more so, defi-
ciency of Beclin-1 enhances tumorigenesis of lym-
phomas, lung carcinomas, hepatocellular carcinomas 
and mammary precancerous lesions in mice (135). 
Secondly, FOXO1, except as transcription factor to 
induce the expression of tumor suppression genes, 
alternatively can bind to ATG7 to activate the au-
tophagic cell death, hereby antagonizing tumor de-
velopment (1). Why and how this FOXO1 related 
function is silenced during tumorigenesis is yet un-
clear. However, it was recently found by Zhao et al 
(136) that the unspliced form of XBP-1(XBP-1u) can 
promote ubiquitin-independent proteasomal degra-
dation of FOXO1 and may thus be considered as an 
oncogene stimulating tumor initiation.  
On the other hand, autophagy can be 
up-regulated to support tumor development, e.g. 
under hypoxic conditions, tumor cells require au-
tophagy to cope with the low nutrient availability 
(137). In addition, autophagy may provide tumor cells 
with resistance to chemotherapy (138).  
So, it seems that impaired autophagy can both 
enhance and lower the risk of tumorigenesis (139). 
Which of these effects prevail likely is dependent on 
the stage of tumor, tumor physiology and the tissue 
from which the tumor originated. 
(b) Liver diseases 
The liver, the most important tissue for organ-
ismal metabolism, is responsible for: 1) amino acid 
metabolism (synthesis and degradation), 2) glucose 
metabolism (gluconeogenesis, glycogenolysis and 
glycogenesis), 3) lipid metabolism (cholesterol syn-
thesis, lipogenesis and lipoproteins synthesis), 4) 
blood cell regeneration, blood ingredient replenish-
ment and coagulation reaction, 5) endocrine system 
homeostasis (secretion of IGF-1, breakdown of insulin 
and other hormones), 6) detoxification (endogenous 
toxic metabolic products and exogenous medicine) 
and 7) completion of immunological effects. Not sur-
prisingly, autophagy is a critical process in hepato-
cytes, and abnormal autophagy has been observed in 
many pathological liver-related disorders, such as 
insulin resistance, nonalcoholic steatohepatitis 
(NASH), cirrhosis, viral hepatitis, hepatic steatosis, 
mutant α1-Antitrypsin Z protein related diseases and 
liver cancer (140). What kind of role autophagy is 
playing in these diverse liver pathologies is still 
largely unknown. Recently, we revealed that in pol-
ycystic liver disease (PCLD), autophagy is activated 
by the deficiency of hepatocystin, of which mutants 
have been shown to cause PCLD (141). Therefore, in 
PCLD, autophagy inhibition might be a strategy to 
delay pathogenesis.  
(c) Brain and neurodegenerative diseases 
Autophagy has been shown as an essential pro-
cess for the maintenance of neuronal function (124). 
This theory is supported by the observation that in 
neurodegeneration such as Alzheimer's, Parkinson's, 
Huntington's disease and amyotrophic lateral sclero-
sis (ALS) protein aggregates have accumulated indic-
ative of disturbed proteostasis, including impaired 
autophagy. Indeed, several lines of evidence support 
that boosting autophagy in such diseases may have 
beneficial effects (142-144). However, 
over-stimulating autophagy has the risk to become 
cytotoxic and pro-degenerative. Therefore, besides 
increasing the autophagic flux, improving cargo 
(protein aggregate) delivery into autophagosomes 
seems a promising strategy to counteract neuro-
degeneration. This might be accomplished by e.g. 
stimulating proteins like Alfy (145), or boosting cer-
tain HSP like HSPB7 (115, 146). 
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CONCLUSION AND PERSPECTIVES  
Autophagy is not merely a strategy of cellular 
catabolism to recycle proteins and other nutrients, but 
also responsible for many other cellular functions, 
such as cellular quality control which requires proper 
clearance of misfolded proteins, damaged organelles, 
and sometimes ensuring clearance of damaged cells. 
Although the regulation of the autophagic network 
has been comprehensively investigated in the recent 
decades, it is still controversial whether a dysfunc-
tional autophagy is actually the cause for a disease or 
just an indicator of upstream protective response that 
has failed to protect cells and tissues from an injury. 
Nevertheless, boosting the autophagic flux has shown 
the significant benefits in various disease models (116, 
119, 132, 143), implying that its activity at least does 
influence progression of certain diseases. How to 
modulate the autophagic network precisely to do so 
without impeding on normal cellular physiology, i.e. 
avoiding toxicity, will however remain a major chal-
lenge. Precise knowledge on the many different sig-
naling pathways that are involved in the regulation of 
the autophagic network will therefore be crucial and 
require co-induction of upstream protective pathways 
such that damage clearance is also accompanied by 
preventing further damage. As such, the coordinated 
inhibition of the insulin pathways probably sets the 
best example. Here, longevity and stress resistance 
seems is not associated with induction of autophagy, 
but also with an increase in molecular chaperones, 
and improved proteolytic activity (figure 6) (147, 148).  
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